Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Common Equity: 2024

Historic Common Equity for Pyxis Oncology (PYXS) over the last 1 years, with Dec 2024 value amounting to $120.8 million.

  • Pyxis Oncology's Common Equity fell 55.25% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year decrease of 55.25%. This contributed to the annual value of $120.8 million for FY2024, which is N/A change from last year.
  • Pyxis Oncology's Common Equity amounted to $120.8 million in FY2024.
  • Pyxis Oncology's 5-year Common Equity high stood at $120.8 million for FY2024, and its period low was $120.8 million during FY2024.
  • For the 1-year period, Pyxis Oncology's Common Equity averaged around $120.8 million, with its median value being $120.8 million (2024).